McDermott Will & Emery represented Inhibikase Therapeutics in the transaction.Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course…
Inhibikase Therapeutics’ $4 Million Common Stock Offering
